Last reviewed · How we verify
Tetanus-diphteria
This vaccine stimulates the immune system to produce antibodies against tetanus toxin and diphtheria toxin, providing active immunization against both diseases.
This vaccine stimulates the immune system to produce antibodies against tetanus toxin and diphtheria toxin, providing active immunization against both diseases. Used for Active immunization against tetanus and diphtheria in adolescents and adults, Booster vaccination for tetanus and diphtheria protection.
At a glance
| Generic name | Tetanus-diphteria |
|---|---|
| Sponsor | Hospital Clinic of Barcelona |
| Drug class | Toxoid vaccine |
| Target | Tetanus toxin (tetanospasmin) and diphtheria toxin |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Tetanus-diphtheria (Td) vaccine contains inactivated toxoids from Clostridium tetani and Corynebacterium diphtheriae. These toxoids are chemically inactivated bacterial toxins that trigger B-cell and T-cell responses without causing disease. The resulting antibodies neutralize the actual toxins produced during natural infection, preventing tetanus and diphtheria.
Approved indications
- Active immunization against tetanus and diphtheria in adolescents and adults
- Booster vaccination for tetanus and diphtheria protection
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Myalgia
- Headache
- Fatigue
Key clinical trials
- Exploratory Clinical Study of MT-2301 (PHASE2)
- Phase 3 Study of BK1310 in Healthy Infants (PHASE3)
- Pertussis Immunization During Pregnancy & HIV Infection
- Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children (NA)
- Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines (PHASE3)
- Evaluation of a Tdap-IPV (Tetanus, Diphteria, Pertussis and Inactivated Polio) Vaccination Remedial Strategy on Vaccination Coverage in Patients 65 Years of Age or Older (NA)
- Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell Transplantation (PHASE3)
- Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Old (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |